AI Assessment Finds 50 National Cancer Plans Score Median 2.78, Financing Among Weakest Areas

National cancer control plans across 50 countries scored a median 2.78 out of five for comprehensiveness, with financing, outcome measurement and contextual analysis emerging as the weakest areas, according to an AI-supported assessment published in The Lancet Oncology.

The study used a validated multiagent AI system called the policy reasoning integrated sequential model (PRISM) to evaluate the most recent eligible national cancer control plan for each country. Researchers built an analytical framework of 12 elements and 76 sub-elements informed by international cancer control guidance, validated through a modified two-stage Delphi process involving 67 experts in an online survey and 31 workshop participants.

PRISM combined document ingestion, AI-supported policy analysis using retrieval-augmented generation, and semantic quality assurance, and its performance was assessed against independent dual-expert ratings of six selected plans before being applied across the full dataset.

National Cancer Plans Score Moderately on Comprehensiveness in Global AI-Assisted Review — MedAI Digest

European countries achieved the highest regional median score at 2.96, while the Western Pacific region recorded the lowest at 2.21. Among income groups, lower-middle-income countries had the highest median score at 2.97, compared with 2.05 in low-income countries.

At the element level, implementation achieved the highest median score at 4.17, followed by health services at 3.89 and governance and organisation at 3.67. Conversely, financing scored 1.88, outcomes 1.83, and threats 2.19. The financing element showed a particularly large gap, with five of its 11 sub-elements receiving median scores of 1.0 or below.

The researchers propose that shared health systems frameworks and scalable AI assessment tools such as PRISM could support more consistent comparisons between countries, and that rapid appraisal may help policymakers develop timely, achievable, evidence-informed and context-specific cancer control plans incorporating the latest available data.